53 completed, 31 terminated, 28 recruiting, 24 unknown. 164 Phase 2, 37 Phase 1, 7 Phase 3.
Follow Diffuse Large B-Cell Lymphoma: new trials by email Literature Review of Diffuse Large B-Cell Lymphoma trials Research Report on Diffuse Large B-Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial of MK-1045 With Zilovertamab Vedotin in Participants With Diffuse Large B-cell Lymphoma (MK-1045-010) MK-1045, Zilovertamab vedotin, Rituximab - Lymphoma, Large B-Cell, Diffuse, Diffuse Large B-Cell Lymphoma | Phase 2 / Phase 3 | Not yet recruiting | Merck Sharp & Dohme LLC | 470 | 2026-12-13 | 2026-11-05 |
| MRD-Adapted Low-Dose Radiation Therapy During Frontline Chemoimmunotherapy for Diffuse Large B-Cell Lymphoma Low-Dose Radiation Therapy (LDRT), Standard Frontline Chemoimmunotherapy - Diffuse Large B-Cell Lymphoma | Phase 2 | Not yet recruiting | University of Nebraska | 50 | 2026-12-12 | 2026-11-06 |
| Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Richter Syndrome, Diffuse Large B-Cell Lymphoma | Phase 2 | Recruiting | Roswell Park Cancer Institute | 32 | 2026-11-15 | 2026-10-02 |
| A Study of Polatuzumab Vedotin and Glofitamab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Within 12 Months After R-CHOP Polatuzumab vedotin, Glofitamab - Diffuse Large B-cell Lymphoma | Phase 2 | Not yet recruiting | Yonsei University | 47 | 2026-09-01 | 2026-07-14 |
| A Study of BL-M08D1 in Combination With Immunochemotherapy in Patients With Diffuse Large B-Cell Lymphoma BL-M08D1, Rituximab, Gemcitabine Hydrochloride - Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Not yet recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 204 | 2026-09-01 | 2026-09-14 |
| Chidamide Maintenance for MRD-Positive Double-Expressor DLBCL in First Complete Remission Chidamide - Diffuse Large B-Cell Lymphoma | Phase 2 | Recruiting | Rong Tao | 69 | 2026-06-16 | 2026-06-18 |
| G-Pola-ZLP in Diffuse Large B-Cell Lymphoma Glofitamab, Polatuzumab Vedotin, Zanubrutinib, Lenalidomide and Prednisone as Induction Therapy - Diffuse Large B-Cell Lymphoma | Phase 2 | Not yet recruiting | Navy General Hospital, Beijing | 80 | 2025-09-24 | 2025-08-14 |
| Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Homoharringtonine, BCL-2 inhibitor, CD20 Antibody - Diffuse Large B-Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Not yet recruiting | First Affiliated Hospital of Zhejiang University | 62 | 2025-09-08 | 2025-09-08 |
| DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12) DZD8586+R-CHOP, DZD8586+R-GemOx, DZD8586+BR - Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Dizal Pharmaceuticals | 150 | 2025-08-19 | 2026-04-01 |
| Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL Glofitamab, Polatuzumab Vedotin, Zanubrutinib - Diffuse Large B-Cell Lymphoma | Phase 2 | Recruiting | Shanghai Zhongshan Hospital | 38 | 2025-06-20 | 2026-10-16 |
| Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+ Zanubrutinib - Diffuse Large B-cell Lymphoma, DLBCL - Diffuse Large B Cell Lymphoma | Phase 2 | Recruiting | Virginia Commonwealth University | 21 | 2025-05-27 | 2026-01-23 |
| Evaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined With Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) as Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients Ineligible for Autologous Transplantation Polatuzumab Vedotin combined with Rituximab, Gemcitabine, and Oxaliplatin (Pola-R- GemOx) - Diffuse Large B-Cell Lymphoma | Phase 2 | Recruiting | Fudan University | 130 | 2025-05-08 | 2025-06-19 |
| A Study of R-mini-MCOP in the Treatment of Elderly, Previously Untreated DLBCL R-miniMCOP:Rituximab / Mitoxantrone Liposome / Cyclophosphamide / Vincristine / Prednisone - Diffuse Large B-Cell Lymphoma | Phase 2 | Not yet recruiting | Xiaohui He | 33 | 2025-04-16 | 2025-04-10 |
| Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL Polatuzumab vedotin, Rituximab, Cyclophosphamide - Diffuse Large B-Cell Lymphoma | Phase 2 | Recruiting | Ruijin Hospital | 152 | 2025-04-01 | 2025-12-08 |
| CHiR Therapy for Elderly DLBCL Intolerant to Chemo CHiR-DEL - Diffuse Large B-Cell Lymphoma | Phase 2 | Recruiting | First Affiliated Hospital of Ningbo University | 30 | 2025-02-01 | 2025-03-19 |
| Clinical Study of HiR+X Therapy for Newly Diagnosed Elderly Patients With DLBCL Intolerant to Chemotherapy Drug therapy - DLBCL, Diffuse Large B-Cell Lymphoma | Phase 2 | Recruiting | First Affiliated Hospital of Ningbo University | 50 | 2025-01-15 | 2025-03-18 |
| Safety and Efficacy of R-CMOP Versus R-CHOP in the Initial Treatment of DLBCL R-CMOP Regimen, R-CHOP Regimen - Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Sun Yat-sen University | 112 | 2025-01-10 | 2025-04-03 |
| Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL Polatuzumab vedotin, Rituximab, Cyclophosphamide - Diffuse Large B-Cell Lymphoma | Phase 2 | Not yet recruiting | Ruijin Hospital | 152 | 2024-12-31 | 2024-06-04 |
| Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients With Late Relapse of Diffuse Large B-Cell Lymphoma Axicabtagene Ciloleucel - DIFFUSE LARGE B-CELL LYMPHOMA | Phase 2 | Recruiting | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | 45 | 2024-11-20 | 2025-11-28 |
| Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL Large fraction radiotherapy in combined with GM-CSF, Lenalidomide, and Glofitamab - Diffuse Large B-cell Lymphoma, Relapsed and Refractory | Phase 2 | Recruiting | The First Affiliated Hospital of Xiamen University | 22 | 2024-10-21 | 2025-07-23 |
Showing 20 of 164. Sign in to see all of them.
Lymphoma, Large B-Cell, Diffuse (164) · Lymphoma (19) · Lymphoma, Non-Hodgkin (19) · Recurrence (19) · Lymphoma, Mantle-Cell (16) · Leukemia, Lymphocytic, Chronic, B-Cell (12) · Lymphoma, Follicular (12) · Burkitt Lymphoma (7) · Lymphoma, B-Cell, Marginal Zone (7) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (5) · Hodgkin Disease (4) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (4) · Lymphoma, B-Cell (4) · Multiple Myeloma (4) · Waldenstrom Macroglobulinemia (4)
Hemic and Lymphatic Diseases (164) · Immune System Diseases (164) · Neoplasms by Histologic Type (164) · Immunoproliferative Disorders (163) · Lymphatic Diseases (163) · Lymphoproliferative Disorders (163) · Neoplasms (163) · Lymphoma, B-Cell (160) · Lymphoma (145) · Lymphoma, Non-Hodgkin (145) · Pathologic Processes (32) · Pathological Conditions, Signs and Symptoms (32) · Disease Attributes (30) · Hematologic Diseases (16) · Leukemia, Lymphoid (14)
Rituximab (68) · Cyclophosphamide (33) · Prednisone (27) · Vincristine (24) · Doxorubicin (22) · Lenalidomide (22) · polatuzumab vedotin (14) · Gemcitabine (13) · Etoposide (12) · Bendamustine Hydrochloride (11) · Oxaliplatin (10) · Dexamethasone (9) · zanubrutinib (8) · tafasitamab (7) · N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide (6)
Fudan University (5) · Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea (5) · National Cancer Institute (NCI) (5) · Fondazione Italiana Linfomi - ETS (4) · Genmab (4) · Ruijin Hospital (4) · Gilead Sciences (3) · Merck Sharp & Dohme LLC (3) · Millennium Pharmaceuticals, Inc. (3) · Navy General Hospital, Beijing (3) · Sanofi (3) · UNC Lineberger Comprehensive Cancer Center (3) · ADC Therapeutics S.A. (2) · Asan Medical Center (2) · AstraZeneca (2)
United States (72) · China (37) · Italy (30) · Spain (26) · France (21) · United Kingdom (19) · Belgium (13) · Czechia (11) · Germany (11) · Poland (11) · Canada (10) · Australia (9) · Israel (9) · South Korea (9) · Austria (8)
Ye Guo, MD (3) · Carlos Grande, MD (2) · Christopher J Melani, M.D. (2) · Dipenkumar Modi, M.D. (2) · Liren Qian, PhD (2) · Luis Palomera, MD (2) · Michele Spina, MD (2) · Reem Karmali, MD (2)
PMID 38775302, PMID 39319495, PMID 40802906, PMID 17242396, PMID 18213528, PMID 18559976, PMID 18824292, PMID 1950172, PMID 20548096, PMID 20686505, PMID 21390126, PMID 21482186, PMID 21495023, PMID 21796119, PMID 22080169, PMID 22339555, PMID 22362161, PMID 22851565, PMID 22882209, PMID 23144193, PMID 23247661, PMID 23799873, PMID 23834234, PMID 23955074, PMID 24403232, PMID 24625556, PMID 24721323, PMID 25361987, PMID 25652253, PMID 25696919, PMID 25712263, PMID 26232170, PMID 26373676, PMID 26755709, PMID 26968534, PMID 27209293, PMID 27282998, PMID 27717585, PMID 28219694, PMID 28381416, PMID 29748443, PMID 29748444, PMID 29752199, PMID 29903707, PMID 30082475, PMID 30620669, PMID 30770362, PMID 30935953, PMID 30975638, PMID 31073022
2014 (3), 2023 (3), 2009 (2), P01CA078902 (2), P30CA015704 (2), P30CA022453 (2), 2004 (1), 2008 (1), 2015 (1), 2016 (1), 2018 (1), 2019 (1), 2025 (1), K01TW009488 (1), P30CA014599 (1)